Methenamine hippurate EQL Pharma approved
The pharmaceutical Methenamine hippurate EQL Pharma, tablet 1g, has been approved for sale by the Medicine Products Agencies in Sweden, Denmark and the United Kingdom. In the UK, the product will be licensed to a local partner, Advanz Pharma Corp.
Methenamine hippurate EQL Pharma is a pharmaceutical that is taken as a prophylaxis against recurrent urinary tract infections.
Methenamine hippurate EQL Pharma contains methenamine, a substance that has been registered in Sweden since 1973. Methenamine hippurate EQL Pharma becomes the first and only generic available on the markets where it is registered. The market for methenamine 1g tablet is medium sized in the countries concerned with about 35.5 MSEK in total annual sales, of which about half is in the UK
The product is expected to be launched during the fourth quarter, 2019.
For further information, please contact:
CEO EQL Pharma AB (publ)
Phone: +46 (0) 705 – 60 90 00
About EQL Pharma
EQL Pharma specializes in developing and selling generics, i.e. medicines that are medically equivalent to originator pharmaceuticals. The company is currently marketing 13 niche generics (i.e. generics with little or no competition apart from the originator pharmaceutical) in the Swedish and Danish markets, in addition to which there is a significant pipeline of additional niche generics for launch in 2019 and onwards. The business is currently fully focused on prescription drugs. EQL Pharma operates in Lund, employs 8 (7) people and is listed on the Spotlight Stock Market. EQL Pharma is engaged in extensive development work in collaboration with leading contract manufacturers and major pharmaceutical companies in, for example, Europe, India and China.